Translumina’s Vivo Isar Dual-Drug Polymer-Free Coated Stent Launched in International Markets

April 19, 2022—Translumina announced the launch of the Vivo Isar dual-drug polymer-free coated stent in various international markets including Europe.

The company has launched the Vivo Isar drug-eluting stent (DES) in Italy and Spain and plans to roll it out in several markets across Europe, Latin America, and Asia-Pacific regions over the coming months. Translumina is based in New Delhi, India, and Hechingen, Germany.

According to Translumina, the Vivo Isar device combines a stent with a superior safety profile without compromising the drug release kinetics. The polymer-free DES platform uses probucol, an antioxidant and lipid-lowering drug, as a carrier for releasing the antirestonic drug sirolimus.

In August 2020, Translumina announced that 10-year follow-up safety and efficacy data from the ISAR TEST-5 study comparing the Vivo Isar device to the Endeavour Resolute DES (Medtronic) were published by Professor Sebastian Kufner, MD, et al in Journal of the American College of Cardiology (2020;76:146-158). Prof. Kufner presented the 10-year ISAR TEST-5 data at the American Heart Association scientific sessions in November 2019.

Adnan Kastrati, MD, who is Director, Cardiac Catheterization Lab, German Heart Center, in Munich, Germany, serves as lead investigator of ISAR TEST-5 study. In Translumina’s press release, Dr. Kastrati commented, “The 10-year outcome of Vivo Isar is a major breakthrough in DES technology as it proves that synthetic polymers can be removed from a DES without compromising the efficacy of the DES. The excellent safety profile demonstrated in the 10-year follow-up study is especially notable as it provides a powerful new technology for treating complex coronary artery disease in high-risk patient subsets. This DES technology carries the great potential of significantly shortening the duration of dual antiplatelet therapy.”